Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs CVS Health Corp (CVS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs CVS Health Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while CVS Health Corp trades at $104.15 (market cap $132.89B). The key difference: CVS Health Corp is far larger — about 3.3× Alnylam Pharmaceuticals, Inc.'s market cap, and CVS Health Corp pays a 2.55% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CVS | |
|---|---|---|
Market Cap | $39.89B | $132.89B |
Sector | Health | Health |
52-Week High | $491.22 | $104.81 |
52-Week Low | $278.09 | $58.75 |
Enterprise Value | $38.15B | $199.43B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CVS Health trades at $104.15, up 1.3% with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats with Q1 2026 EPS of $2.57 exceeding expectations of $2.18. Revenue growth remains robust at $402.07B for 2025, though net margins have compressed to 0.72%. Recent dividend declarations and positive media coverage highlight the company's stable cash flow generation and market positioning.
CVS presents a compelling investment case with 84.6% analyst buy ratings and a $107.29 consensus target offering 3% upside. However, investors face risks from declining profitability margins, elevated debt levels at 25.48% debt-to-asset ratio, and competitive pressures in the healthcare sector. The stock's current valuation at 45.68 P/E requires careful monitoring of margin improvement initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
